ReviewCancers2022
Microbial-Derived Toll-like Receptor Agonism in Cancer Treatment and Progression.
Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 15 citations in OpenAlex.
- Toll-Like Receptors in the Mechanism of Hexabromocyclododecane-Induced Production of Pro-Inflammatory Cytokines.Journal of applied toxicology : JAT · 2026Article
- Synthetic Toll-Like Receptors for Control of Innate Immunity With Far-Red Light.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Bacterial colonization of tumors drives immune activation and checkpoint blockade efficacy.Scientific reports · 2026Article
- Bacterial RNA downregulates MHC-I in tumor cell lines, promoting NK response and delaying tumor growth.PloS one · 2026Article
- Recent Advances in Immune Regulation by Targeting Dendritic Cells using Small Interfering RNAs.Current molecular medicine · 2025Review
- Toll-like Receptors: Key Players in Squamous Cell Carcinoma Progression.Journal of clinical medicine · 2024Article
- Analysis of Selected Toll-like Receptors in the Pathogenesis and Advancement of Non-Small-Cell Lung Cancer.Journal of clinical medicine · 2024Article
- Unraveling the Complexities of Toll-like Receptors: From Molecular Mechanisms to Clinical Applications.International journal of molecular sciences · 2024Review
- Regulation of immune responses to infection through interaction between stem cell-derived exosomes and toll-like receptors mediated by microRNA cargoes.Frontiers in cellular and infection microbiology · 2024Review
- Design of a potential Sema4A-based multi-epitope vaccine to combat triple-negative breast cancer: an immunoinformatic approach.Medical oncology (Northwood, London, England) · 2023Article
- Molecular and Cellular Mechanisms of Propolis and Its Polyphenolic Compounds against Cancer.International journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Toll-like receptors (TLRs) are typical transmembrane proteins, which are essential pattern recognition receptors in mediating the effects of innate immunity. TLRs recognize structurally conserved molecules derived from microbes and damage-associated molecular pattern molecules that play an important role in inflammation. Since the first discovery of the Toll receptor by the team of J. Hoffmann in 1996, in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.